78 related articles for article (PubMed ID: 38715777)
1. Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient.
Tamura A; Inaba Higashiyama R; Yoshida T; Satozono Y; Ohe Y
Thorac Cancer; 2024 Jun; 15(18):1454-1456. PubMed ID: 38766698
[TBL] [Abstract][Full Text] [Related]
2. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.
Ueberroth BE; Lieu CH; Lentz RW
J Gastrointest Cancer; 2024 May; ():. PubMed ID: 38814411
[TBL] [Abstract][Full Text] [Related]
3. A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination.
Singh M; Cornwell S; Shaddaie A; Wachsmuth L; Ragupathi A; Salichos L; Nissel-Horowitz S; Roy R; Plummer M; Zhang D; Mehrotra B
Gynecol Oncol Rep; 2024 Aug; 54():101417. PubMed ID: 38808271
[TBL] [Abstract][Full Text] [Related]
4. Targeting the RAS upstream and downstream signaling pathway for Cancer treatment.
Hossain MA
Eur J Pharmacol; 2024 Jun; ():176727. PubMed ID: 38866361
[TBL] [Abstract][Full Text] [Related]
5. Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience.
Sbrana A; Cappelli S; Petrini I; Bernardini L; Massa V; Carrozzi L; Chella A
Future Oncol; 2024 May; ():1-7. PubMed ID: 38709118
[TBL] [Abstract][Full Text] [Related]
6. [Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK].
Messekher M; François H; Denis MG; Ferrer-Lopez P; Bost-Bezeaud F; Mazières J; Parrat E
Rev Mal Respir; 2024 Jun; 41(6):451-454. PubMed ID: 38796386
[TBL] [Abstract][Full Text] [Related]
7. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success.
Wang M; Sullivan RJ; Mooradian MJ
Curr Oncol Rep; 2024 Jun; ():. PubMed ID: 38850505
[TBL] [Abstract][Full Text] [Related]
8. Exceptional Clinical Response to BRAF-Targeted Therapy in a Patient with Metastatic Sarcoma.
Mitsis D; Opyrchal M; Zhao Y; Kane Iii JM; Cheney R; Salerno KE
Cureus; 2015 Dec; 7(12):e439. PubMed ID: 26858920
[TBL] [Abstract][Full Text] [Related]
9. A critical review of RAF inhibitors in BRAF-mutated glioma treatment.
Khoury JE; Wehbe S; Attieh F; Boutros M; Kesrouani C; Kourie HR
Pharmacogenomics; 2024 Jun; ():1-13. PubMed ID: 38884947
[TBL] [Abstract][Full Text] [Related]
10. Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer.
Panagiotou E; Vathiotis IA; Makrythanasis P; Hirsch F; Sen T; Syrigos K
Lancet Respir Med; 2024 Jun; ():. PubMed ID: 38885686
[TBL] [Abstract][Full Text] [Related]
11. A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review.
Sharma P; Mahadevia H; Donepudi S; Kujtan L; Gustafson B; Ponvilawan B; Al-Obaidi A; Subramanian J; Bansal D
Clin Lung Cancer; 2024 Apr; ():. PubMed ID: 38777674
[No Abstract] [Full Text] [Related]
12. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
13. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
Xue Y; Ren Y; Yan B; Li Z; Huang C
Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
[TBL] [Abstract][Full Text] [Related]
14. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
Sánchez-Torres JM; Viteri S; Molina MA; Rosell R
Transl Lung Cancer Res; 2013 Jun; 2(3):244-50. PubMed ID: 25806238
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
16. Case report: Dual dabrafenib and trametinib therapy for treating BRAF V600E mutated lung adenocarcinoma with BRCA2 germline mutation post multiline progression.
Zhang H; Cong X; Yin J; Chen C; Liu Z
Front Oncol; 2024; 14():1387388. PubMed ID: 38715777
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
